Results of a new study show that IsoPSA, a novel prostate-specific antigen assay, is readily adopted by practitioners in various practice settings, and its use significantly reduces biopsies in men being evaluated for elevated PSA.
Experts at Cleveland Clinic have invested in research and technology designed to improve outcomes and patient experience.
Cleveland Clinic is now offering the IsoPSA™ test, a novel prostate-specific antigen assay, for patients with a PSA > 4ng/ml who are facing a decision on prostate biopsy.
The IsoPSA prostate-specific antigen test could reduce unnecessary prostate biopsies by more than 40% while reliably differentiating among high-grade, low-grade and benign disease, a new validation study has found.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic researchers cover the gamut when it comes to prostate cancer investigation, from elucidating mechanisms behind resistance to therapy to developing more precise diagnostics.